Table 1.
Demographic details of the two different patient cohorts used for genotyping and gene expression studies.
| 225 patients for ADORA polymorphisms | 20 patients for synovial gene expression | |
|---|---|---|
| Age (years) | 59.5 (18 to 84) | 66.4 (48 to 80) |
| % Female | 72% | 90% |
| Disease duration (years) | 10.4 (0.17 to 57) | 21.1 (3.7 to 47) |
| Nodules | 56 (24.9%) | 12 (60%) |
| Erosions | 139 (61.8%) | 19 (95%) |
| RF +positive | 178 (79.1%) | 17 (85%) |
| CCP positive | 165/214 (77.1%) | 11/15 (73.3%) |
| Receiving MTX | 225 (100%) | 11 (55%) |
| MTX dose (mean) (mg/wk) | 15.8 (5 to 25) | 16.4 (7.5 to 20) |
| ESR | 16.6 (2 to 96) | 41.4 (14 to 74) (n = 10) |
| CRP | 10.9 (0 to 150) | 18.9 (3 to 79) (n = 17) |
| Anti-TNF therapy | 0 | 3 (15%) |
| Prednisone | 71 (31.6%) | 6 (30%) |
ADOR, adenosine receptor; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MTX, methotrexate; TNF, tumor necrosis factor; RF, rheumatoid factor.